The clonoSEQ report

Disease burden at your fingertips

clonoSEQ MRD testing can be ordered throughout the treatment continuum in lymphoid cancer care. A baseline test, the Clonality (ID) Test, is required to enable subsequent MRD tracking.

Looking for clonoSEQ results? Visit our Diagnostic Portal

  • Identifies dominant sequences from the patient’s cancer cells so they can be monitored over time
  • Uses a high disease-burden bone marrow/blood sample from a specimen obtained at diagnosis or relapse
  • For CLL patients, immunoglobulin heavy chain variable region (IGHV) mutation status is included with the Clonality (ID) Test

Tap numbers on the report for more information.

  • Visually monitors dominant trackable DNA sequences identified by the Clonality (ID) Test and detects any newly emerging sequences
  • Detects changes in disease burden over time
  • Supports routine MRD monitoring throughout treatment and monitoring for potential relapse in remission

Tap numbers on the report for more information.

MCL, mantle cell lymphoma.


This page is intended for a US-based audience.

clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary.